We are live on ! Find out more
APM

Avidity Partners Management Portfolio holdings

AUM $936M
1-Year Est. Return 195%
This Fund
S&P 500
This Quarter Est. Return
+30.52%
1 Year Est. Return
+195%
3 Year Est. Return
+460.87%
5 Year Est. Return
+815.5%
10 Year Est. Return
–
AUM
$2.74B
AUM Growth
+$261M
Cap. Flow
-$140M
Cap. Flow %
-5.1%
Top 10 Hldgs %
32.74%
Holding
95
New
12
Increased
24
Reduced
31
Closed
21

Top Buys

Rank Stock Value
1
TMO icon
Thermo Fisher Scientific
TMO
+$88.4M
2
UTHR icon
United Therapeutics
UTHR
+$54.7M
3
CVS icon
CVS Health
CVS
+$52.7M
4
AVTR icon
Avantor
AVTR
+$43.5M
5
ABBV icon
AbbVie
ABBV
+$41.5M

Top Sells

Rank Stock Value
1
CI icon
Cigna
CI
+$60.7M
2
SRPT icon
Sarepta Therapeutics
SRPT
+$54.5M
3
MLTX icon
MoonLake Immunotherapeutics
MLTX
+$44.3M
4
ZNTL icon
Zentalis Pharmaceuticals
ZNTL
+$42.1M
5
JAZZ icon
Jazz Pharmaceuticals
JAZZ
+$38.5M

Sector Composition

Rank Sector Weight
1 Healthcare 95.29%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
HUM icon
26
Humana
HUM
$45.8B
$45.8M 1.67%
100,000
-10,300
-9% -$5.08M
ABBV icon
27
AbbVie
ABBV
$454B
$44.1M 1.61%
+284,405
New +$41.5M
GPCR icon
28
Structure Therapeutics
GPCR
$3.46B
$44M 1.6%
1,080,000
+580,000
+116% +$33.2M
ALGN icon
29
Align Technology
ALGN
$12B
$42.7M 1.56%
+155,800
New +$36.9M
LEGN icon
30
Legend Biotech
LEGN
$3.73B
$41.2M 1.5%
685,000
-282,000
-29% -$17.9M
BDX icon
31
Becton Dickinson
BDX
$43.8B
$40.4M 1.47%
165,706
-121,094
-42% -$29.8M
RARE icon
32
Ultragenyx Pharmaceutical
RARE
$2.65B
$40.4M 1.47%
844,500
+300,500
+55% +$11.6M
MCK icon
33
McKesson
MCK
$99.5B
$39.6M 1.44%
85,500
-80,800
-49% -$36.7M
XENE icon
34
Xenon Pharmaceuticals
XENE
$6.36B
$37.6M 1.37%
815,993
+494,593
+154% +$17.5M
SGRY icon
35
Surgery Partners
SGRY
$1.98B
$37.3M 1.36%
1,165,932
-172,068
-13% -$4.99M
AXSM icon
36
Axsome Therapeutics
AXSM
$12.3B
$36.6M 1.33%
459,400
+162,600
+55% +$10.9M
CRBU icon
37
Caribou Biosciences
CRBU
$158M
$36.4M 1.33%
6,360,212
+310,000
+5% +$1.53M
PCVX icon
38
Vaxcyte
PCVX
$8.01B
$35.8M 1.3%
570,137
-186,028
-25% -$9.66M
NMRA icon
39
Neumora Therapeutics
NMRA
$308M
$33.9M 1.24%
1,990,632
+190,632
+11% +$2.34M
MIRM icon
40
Mirum Pharmaceuticals
MIRM
$6.96B
$33.7M 1.23%
1,142,850
– –
UNH icon
41
UnitedHealth
UNH
$379B
$30.8M 1.12%
58,500
-53,700
-48% -$28.6M
PRVA icon
42
Privia Health
PRVA
$3.11B
$29.6M 1.08%
1,287,000
-258,100
-17% -$5.78M
ISRG icon
43
Intuitive Surgical
ISRG
$128B
$28.7M 1.05%
+85,000
New +$25.3M
GPCR icon
44
CALL
Structure Therapeutics
GPCR
$3.46B
$24.5M 0.89%
+600,000
New +$34.4M
LNTH icon
45
Lantheus
LNTH
$7.03B
$23.6M 0.86%
380,000
-178,400
-32% -$12.1M
ANTX icon
46
AN2 Therapeutics
ANTX
$178M
$23.4M 0.85%
1,140,000
+50,600
+5% +$847K
ACIU icon
47
AC Immune
ACIU
$234M
$22.3M 0.81%
4,469,080
+1,499,280
+50% +$4.82M
ARWR icon
48
Arrowhead Research
ARWR
$12B
$21.8M 0.8%
714,000
-349,897
-33% -$9.29M
IMCR icon
49
Immunocore
IMCR
$1.72B
$20.5M 0.75%
300,200
-48,000
-14% -$2.49M
CRNX icon
50
Crinetics Pharmaceuticals
CRNX
$8.87B
$18.8M 0.69%
529,000
-81,000
-13% -$2.48M
1
2
3 4

Similar funds

NM
Newtyn Management New York $936M AUM 27.23% 1-Year Est. Return
PWAM
Private Wealth Asset Management Cedar Rapids, Iowa $935M AUM 17.66% 1-Year Est. Return
LJAC
L.J. Altfest & Co New York $935M AUM 27.19% 1-Year Est. Return
NI
NetEase Inc Hangzhou, China $934M AUM 11.31% 1-Year Est. Return
MCM
Massar Capital Management Stamford, Connecticut $934M AUM 14.18% 1-Year Est. Return
TS
Tamar Securities Woodland Hills, California $934M AUM 26.74% 1-Year Est. Return
TW
TritonPoint Wealth Chevy Chase, Maryland $934M AUM 23.95% 1-Year Est. Return
PGA
Portland Global Advisors Portland, Maine $938M AUM 13.22% 1-Year Est. Return

Avidity Partners Management's Q4 2023 Portfolio in Review

As of Q4 2023, Avidity Partners Management held 95 positions worth $2.74B, up 11% from $2.48B the previous quarter. Its ten largest holdings account for 33% of the portfolio.

Avidity Partners Management withdrew a net $140M in Q4 2023, closing 21 positions and reducing 31 holdings. Its most notable exit was Cigna, an estimated $60.7M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 95% of assets, down from 100% a quarter earlier.

Against the trend, Avidity Partners Management opened a new position in Thermo Fisher Scientific worth $96.9M.

  • Avidity Partners Management's largest Q4 2023 buy was Thermo Fisher Scientific: 182,600 shares worth $96.9M.
  • Avidity Partners Management added most to Structure Therapeutics in Q4 2023, an estimated $33.2M increase.
  • Avidity Partners Management's biggest Q4 2023 reduction was Jazz Pharmaceuticals, cutting an estimated $38.5M.
  • Avidity Partners Management fully exited Cigna in Q4 2023, selling an estimated $60.7M.
  • Avidity Partners Management's ten largest holdings make up 33% of its $2.74B portfolio in Q4 2023.
  • Avidity Partners Management opened 12 new positions and closed 21 in Q4 2023.
  • Avidity Partners Management's portfolio value rose 11% quarter-over-quarter to $2.74B.

Based on Avidity Partners Management's 13F filing for Q4 2023, filed 14 Feb 2024.